Sign inJoin waitlistJoin the waitlist

Marcelo Negrao

Assistant Professor, Thoracic/Head and Neck Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2015–2019
Medical Oncology
2013–2016
University of Sao Paulo Medical School
2011–2013

Research

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
New England Journal of Medicine · 2022 · 871 citations
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Clinical Cancer Research · 2018 · Co-first of 24 authors · 345 citations
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2021 · First of 38 authors · 286 citations

John Heymach
50 papers
Jianjun Zhang
40 papers
Don Gibbons
36 papers
Xiuning Le
25 papers
Tina Cascone
24 papers
BS
Boris Sepesi
21 papers
Stephen Swisher
20 papers
Anne Tsao
19 papers
Yasir Elamin
19 papers · 1 as a fellow
Ara Vaporciyan
18 papers
Ferdinandos Skoulidis
17 papers
Lauren Byers
16 papers

Clinical trials

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2029
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2023–2024
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
Principal investigator · Withdrawn · Phase 1, Phase 2
M.D. Anderson Cancer Center
2021
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2021–2027